Vertical Group

The Vertical Group is a private equity and venture capital firm established in 1988, with headquarters in Berkeley Heights, New Jersey, and an additional office in San Mateo, California. The firm specializes in providing growth capital and financing to early-stage and late-stage companies, particularly in the medical technology and biotechnology sectors. Its investment strategy includes buyouts, recapitalizations, and public investments, with typical investment amounts ranging from $0.25 million to over $10 million, and a preference for holding investments for ten years or longer. The Vertical Group is not limited by transaction type or company size, allowing for a flexible approach to its investment activities.

Richard B. Emmitt

Founder / Managing Director

Jack W. Lasersohn

General Partner

John E. Runnells

General Partner

Past deals in Austin, TX

MicroTransponder

Series F in 2025
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

MicroTransponder

Series E in 2022
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.